Summit Clinical Research Acquires Dallas Research Institute to Expand Pinnacle Site Network
Summit Clinical Research Solutions has acquired Dallas Research Institute (DRI) through its integrated site network, Pinnacle Clinical Research. The acquisition enhances Summit's capabilities in metabolic and liver diseases while expanding the company’s presence in the Dallas-Fort Worth metroplex, a key market for clinical research. DRI specializes in trials related to conditions such as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and obesity—areas that align with Summit's core therapeutic focus. Founded in 2024 by Dr. Stephen Harrison and the company, DRI has been led since its inception by Principal Investigator Dr. Pedro Castillo Jr., who will continue his role post-acquisition. Ryan Nagim of LongueVue Capital emphasized how this acquisition aligns with Summit's strategic vision and strengthens Pinnacle’s site network in a high-growth region.
Topics: clinical research healthcare M&A portfolio company activity